MedTrace Logo

Investigation of Rate + Extent of Excretion of Radioactivity in Urine +Faeces After Oral Administration of [14C]AZD2066

NCT00829088 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2009-02-25

No results posted yet for this study

Summary

The aim of this study is to get information about absorption, distribution, metabolism and excretion as well as the tolerability and safety of AZD2066 in healthy male volunteers.

Conditions

Interventions

DRUG

AZD2066

1 dose oral solution

Sponsors & Collaborators

Principal Investigators

  • Emeline Ramos, MD · AstraZeneca R&D, CPU Alderley Park, UK

  • Lars Ståhle, MD · AstraZeneca R&D, Södertälje, Sweden

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
35 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-01-31
Completion
2009-02-28

Countries

  • United Kingdom

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00829088 on ClinicalTrials.gov